By a News Reporter-Staff News Editor at Pharma Business Week -- Zyoxel, the world's leading expert for advanced in vitro 3D liver models for drug discovery and drug testing, has announced preliminary results from a testing by Sanofi on Zyoxel's LiverChipô platform for drug metabolism and pharmacokinetic (DMPK) studies. Sanofi employed a variety of morphological, genetic and functional analyses to fully characterise the LiverChipô system, the full findings of which will be presented as part of Zyoxel's In Vitro Liver Technology Symposium taking place on December 10, 2013 in Oxford, UK (see also Pharmaceutical Companies).
Under the terms of an Equipment Hire Agreement, Sanofi, an integrated global healthcare leader, has been exploring the utility of Zyoxel's LiverChipô platform. During the project, which commenced in December 2012 and involved the installation of a LiverChipô device at a Sanofi research site, the company tested the human hepatocyte LiverChipô system against current industry gold standard 2D plated cultures of primary hepatocytes.
Using LiverChipô, Sanofi's researchers were able to perform in depth DMPK analyses over much longer time courses of up to 6 days, including the accurate monitoring of dose clearance by the cytochrome P450 enzyme superfamily (CYPs), as well as the induction of CYP isoforms during drug metabolism. The study also confirmed that LiverChipô does not suffer from any non-specific drug binding, while the results exhibited good reproducibility, both within individual plates and between replicate experiments.
For further details about the LiverChipô technology, please visit Zyoxel's website. About Zyoxel Zyoxel has developed and fully commercialized the world's most physiologically accurate in vitro 3D liver model. Their products and services are used by pharmaceutical companies to predict the clinical safety and pharmacological properties of new drugs. Zyoxel's platform is based upon innovative technologies developed at the University of Oxford and the Massachusetts Institute of Technology. The company was spun out of Oxford University'sInstitute of Biomedical Engineering in 2009 with investment from Hong Kong multinational CN Innovations Holdings.
Keywords for this news article include: Pharmaceutical Companies, Zyoxel, Technology.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC